During 2020, the company faced rapid technological development, particularly with respect to computing, automation, artificial intelligence, mobile connectivity, communications, and digitization in most of its served markets. The company is making significant investments, organically and through acquisitions, to address the rapid pace of technological change in its served markets and to globalize its manufacturing, research and development, and customer-facing resources in order to be responsive to its customers throughout the world and improve the efficiency of its operations. The company's individual businesses monitor key competitors and customers to gauge relative performance and the outlook for the future, which underscores the importance of mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities. The acquisition of the biopharma business of GE's life sciences division, now known as Cytiva, is expected to provide additional sales and earnings growth opportunities by expanding the business' geographic and product line diversity, including new product and service offerings that complement the company's current biologics workflow solutions. The company has developed return-to-work protocols designed to ensure the health and safety of its employees, customers, and business partners, which reflects its capability to adapt to changing business needs and directions. The company's businesses have activated their business continuity plans in response to the COVID-19 pandemic, which included modifications to business practices and the deployment of capabilities, expertise, and scale to address critical health needs related to COVID-19. The company has developed and made available diagnostic tests for rapid detection of COVID-19 and has provided critical support to firms developing and producing vaccines for COVID-19. The company's operations are affected by worldwide, regional, and industry-specific economic and political factors, and its long-term growth and profitability will depend on its ability to expand its business in high-growth geographies and segments, identify and integrate appropriate acquisitions, and develop innovative and differentiated new products and services. The company expects core sales growth to continue, driven by demand for instruments and consumables related to COVID-19-related testing capabilities as well as supporting customers in pursuit of new COVID-19-related treatments and vaccines. The companyâ€™s ability to effectively address the demands of an increasingly regulated global environment and to improve operational efficiency is critical to its performance. The company has recognized the importance of strategic resource allocation and the integration of technology capabilities to enhance its organizational effectiveness and agility in responding to market dynamics. The ongoing investments in technology infrastructure and the focus on digital transformation are aimed at improving the company's operational flexibility and supporting its strategic objectives. The company's approach to managing its investments and resources reflects a commitment to leveraging IT capabilities to enhance business value and performance outcomes across its diverse operations.